Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
SWOG 1314: A study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for muscle-invasive bladder cancer

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.06.19
Views: 1086

Prof Thomas Flaig - University of Colorado Denver, Denver, USA

Prof Thomas Flaig talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the randomised trial that examined chemotherapy regimens in muscle-invasive bladder cancer to assess the use of statistical biomarkers to predict which patients would respond to chemotherapy.

He describes the methodology behind this trial and the types of biomarkers that were used, along with their effectiveness. These included a biomarker for gemcitabine-cisplatin and one for MVAC.

Prof Flaig discusses future research opportunities, which include refining the use of the COXEN biomarker and correlating genetic information with this.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation